J. Burggraaf

Assessing differential application of thromboprophylaxis regimes related to risk of pulmonary embolism and mortality in COVID-19 patients through instrumental variable analysis

Linda Nab, Chantal Visser, Bas C. T. van Bussel, Albertus Beishuizen et autres

Thrombotic complications are common in Coronavirus disease 2019 (COVID-19) patients, with pulmonary embolism (PE) being the most frequent. Randomised trials have provided inconclusive results on the optimal dosage of thromboprophylaxis in critically ill COVID-19 patients. We utilized data from the multicentre CAPACITY-COVID …

nl, gb, sa, us, fr, be, pt, ir, il (code pays fourni par la source)

External validation of the Leiden Thrombosis Recurrence Risk Prediction models (L-TRRiP) for the prediction of recurrence after a first venous thrombosis in the Heart and Vascular Health study

J. Burggraaf, Kerri L. Wiggins, Nienke van Rein, Saskia le Cessie et autres

Background: Long-term outcome after a first venous thromboembolism (VTE) might be optimized by tailoring anticoagulant treatment duration on individual risks of recurrence and major bleeding. The L-TRRiP models (A-D) were previously developed in data from the Dutch Multiple Environment and Genetic Assessment …

nl, us (code pays fourni par la source)

Tailored anticoagulant treatment after a first venous thromboembolism: protocol of the Leiden Thrombosis Recurrence Risk Prevention (L-TRRiP) study - cohort-based randomised controlled trial

J. Burggraaf, Nienke van Rein, Remy H.H. Bemelmans, Jan Willem van den Berg et autres

INTRODUCTION: Patients with a first venous thromboembolism (VTE) are at risk of recurrence. Recurrent VTE (rVTE) can be prevented by extended anticoagulant therapy, but this comes at the cost of an increased risk of bleeding. It is still uncertain whether patients with …

nl (code pays fourni par la source)

How to predict recurrent venous thromboembolism and bleeding? A review of recent advances and their implications

J. Burggraaf, Nienke van Rein, Frederikus A. Klok, Suzanne C. Cannegieter

After the first venous thromboembolism (VTE), anticoagulant treatment duration should be based on the balance between the risk of recurrence and bleeding. However, this decision is challenging on the individual level. Prediction models that accurately estimate these risks may help selecting patients …

nl (code pays fourni par la source)

Selective Serotonin Reuptake Inhibitor Use and Risk of Major Bleeding during Treatment with Vitamin K Antagonists: Results of A Cohort Study

Sanne Bakker, J. Burggraaf, Marieke J.H.A. Kruip, F.J.M. van der Meer et autres

BACKGROUND: Selective serotonin reuptake inhibitors (SSRIs) may increase the risk of major bleeding by decreasing platelet function or decreasing vitamin K antagonist (VKA) metabolism via cytochrome P450 (CYP) inhibition. AIMS: To determine whether SSRIs are associated with major bleeding during VKA treatment …

nl (code pays fourni par la source)

Lupus anticoagulant associates with thrombosis in patients with COVID‐19 admitted to intensive care units: A retrospective cohort study

Tessa Noordermeer, Roger E. G. Schutgens, Chantal Visser, Emma Rademaker et autres

Background: Thrombosis is a frequent and severe complication in patients with coronavirus disease 2019 (COVID-19) admitted to the intensive care unit (ICU). Lupus anticoagulant (LA) is a strong acquired risk factor for thrombosis in various diseases and is frequently observed in patients …

nl (code pays fourni par la source)

Incidence of thrombotic complications and overall survival in hospitalized patients with COVID-19 in the second and first wave

Fleur H.J. Kaptein, Milou A.M. Stals, M. Grootenboers, S.J.E. Braken et autres

INTRODUCTION: In the first wave, thrombotic complications were common in COVID-19 patients. It is unknown whether state-of-the-art treatment has resulted in less thrombotic complications in the second wave. METHODS: We assessed the incidence of thrombotic complications and overall mortality in COVID-19 patients …

nl (code pays fourni par la source)

Perioperative Management in Patients Using Vitamin K Antagonists: Observational Cohort Study

J. Burggraaf, Nienke van Rein, F.J.M. van der Meer, Willem M. Lijfering

Abstract Background The benefit of periprocedural bridging with low-molecular-weight heparin (LMWH) in patients with atrial fibrillation has been contested by the publication of the BRIDGE trial. Objective This article determines whether publication of the BRIDGE trial has led to less bridging procedures …

nl (code pays fourni par la source)

Compatibility study of adalimumab and the MicronJet600 hollow microneedle by means of aggregate and particle analysis

Justin Jacobse, Stefan Romeijn, Ajay K. Tandon, Wouter ten Voorde et autres

Digoxin with furosemide is efficacious in cutaneous warts

M. Rijsbergen, Tessa Niemeyer‐van der Kolk, G. Hogendoorn, S.T.P. Kouwenhoven et autres

This is a study of the effect of two topically‐applied (i.e. applied to the skin) drugs, digoxin and furosemide, on the healing of viral warts on the skin. It was performed by a group from the Netherlands and Pennsylvania, USA. The investigation …

A Deconvolution Informed Pharmacodynamic Model For The Quantification Of Drug Effects On Highly Pulsatile Endogenous Profiles.

Michiel J. van Esdonk, Jasper Stevens, Piet H. van der Graaf, J. Burggraaf

pk, nl (code pays fourni par la source)

A single infusion of MDCO-216 (ApoA-1 Milano/POPC) increases ABCA1-mediated cholesterol efflux and pre-beta 1 HDL in healthy volunteers and patients with stable coronary artery disease

David Kallend, Joannes A. A. Reijers, S. Eralp Bellibas, Alain Bobillier et autres

AIMS: Apolipoprotein A-1 (ApoA-1), based on epidemiology, is inversely associated with cardiovascular (CV) events. Human carriers of the ApoA-1 Milano variant have a reduced incidence of CV disease. Regression of atherosclerotic plaque burden was previously observed on intravascular ultrasound (IVUS) with ETC-216, …

ch, nl, us (code pays fourni par la source)